CLINICAL TRIALS PROFILE FOR GLEOLAN
✉ Email this page to a colleague
All Clinical Trials for GLEOLAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04305470 ↗ | Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma | Recruiting | NX Development Corp | Phase 3 | 2020-10-28 | This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection surgery. The study is planned to run for 15 months with individual study participation lasting for approximately 2 months. |
| NCT05362409 ↗ | Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma | Not yet recruiting | Alpheus Medical, Inc. | Phase 1 | 2022-05-01 | A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma (HGG) |
| NCT05804370 ↗ | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | Not yet recruiting | NX Development Corp | Phase 3 | 2023-07-01 | This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan (aminolevulinic acid hydrochloride, also referred to as ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real-time detection and visualization of de novo or recurrent epithelial ovarian cancer during tumor debulking. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GLEOLAN
Condition Name
Clinical Trial Locations for GLEOLAN
Trials by Country
Clinical Trial Progress for GLEOLAN
Clinical Trial Phase
Clinical Trial Sponsors for GLEOLAN
Sponsor Name
